Year: 2024
Type: article
Abstract: The author, having worked in pharmaceuticals for several decades, has advised, in confidence, both investors and small to medium-sized enterprises on transitioning healthcare research projects into commercial development, mainly in Europe. He is now semi-retired. This note is written in the hope that his experience will improve the success of small and medium-sized enter-prises in their attempts to get non-academic investment funding and make life easier for investors. Whilst focused on drugs, the broader advice is relevant to other healthcare areas, such as diagnostics and devices.
Source: Precision Nanomedicine
DOI: 10.33218/001c.124008
Author: Mike Eaton
Language: English
Subfield: Accounting
Domain: Social Sciences
Open Access status: diamond
OpenAlex ID: W4402885807